Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler, Soha Bazyar, Sofie Verbeke, Jo Van Dorpe, Valérie Fonteyne, Bram De Laere, Lara Hathout, Ronald Ennis, Salma K Jabbour, Biren Saraiya, Ryan Stephenson, Tina Mayer, Mark Mishra, Zaker Rana, Jason Molitoris, Ana Kiess, Daniel Y Song, Theodore DeWeese, Kenneth J Pienta, Phuoc T Tran, Alejandro Berlin, Cem Onal, Piet Ost, Matthew P Deek
{"title":"有或没有雄激素剥夺治疗的转移导向治疗反应的基因组预测因子。","authors":"Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler, Soha Bazyar, Sofie Verbeke, Jo Van Dorpe, Valérie Fonteyne, Bram De Laere, Lara Hathout, Ronald Ennis, Salma K Jabbour, Biren Saraiya, Ryan Stephenson, Tina Mayer, Mark Mishra, Zaker Rana, Jason Molitoris, Ana Kiess, Daniel Y Song, Theodore DeWeese, Kenneth J Pienta, Phuoc T Tran, Alejandro Berlin, Cem Onal, Piet Ost, Matthew P Deek","doi":"10.1016/j.euo.2025.07.007","DOIUrl":null,"url":null,"abstract":"<p><p>Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.\",\"authors\":\"Philip Sutera, Kim Van der Eecken, Yang Song, Amol C Shetty, Elai Davicioni, James A Proudfoot, Alexander Hakansson, Keara English, Jarey Wang, Ozan Cem Guler, Soha Bazyar, Sofie Verbeke, Jo Van Dorpe, Valérie Fonteyne, Bram De Laere, Lara Hathout, Ronald Ennis, Salma K Jabbour, Biren Saraiya, Ryan Stephenson, Tina Mayer, Mark Mishra, Zaker Rana, Jason Molitoris, Ana Kiess, Daniel Y Song, Theodore DeWeese, Kenneth J Pienta, Phuoc T Tran, Alejandro Berlin, Cem Onal, Piet Ost, Matthew P Deek\",\"doi\":\"10.1016/j.euo.2025.07.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.</p>\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.3000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2025.07.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.07.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.
Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of genomic alterations to provide prognostic and predictive information regarding response to MDT. We found that high-risk (HiRi) mutations in TP53, BRCA1/2, ATM, and Rb1 are poor prognostic markers in omCSPC. In addition, patients harboring HiRi mutations experienced greater benefit from addition of ADT to MDT, indicating that these alterations are predictive biomarkers for treatment intensification. Our results suggest that genetic biomarkers might aid in treatment personalization for patients with omCSPC.
期刊介绍：
Journal Name: European Urology Oncology
Affiliation: Official Journal of the European Association of Urology
Focus:
First official publication of the EAU fully devoted to the study of genitourinary malignancies
Aims to deliver high-quality research
Content:
Includes original articles, opinion piece editorials, and invited reviews
Covers clinical, basic, and translational research
Publication Frequency: Six times a year in electronic format
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
